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White matter is primarily composed of myelin and myelinated axons. Structural and
functional completeness of myelin is critical for the reliable and efficient transmission
of information. White matter injury has been associated with the development of many
demyelinating diseases. Despite a variety of scientific advances aimed at promoting
re-myelination, their benefit has proven at best to be marginal. Research suggests
that the failure of the re-myelination process may be the result of an unfavorable
microenvironment. Astrocytes, are the most ample and diverse type of glial cells in
central nervous system (CNS) which display multiple functions for the cells of the
oligodendrocytes lineage. As such, much attention has recently been drawn to astrocyte
function in terms of white matter myelin repair. They are different in white matter from
those in gray matter in specific regards to development, morphology, location, protein
expression and other supportive functions. During the process of demyelination and
re-myelination, the functions of astrocytes are dynamic in that they are able to change
functions in accordance to different time points, triggers or reactive pathways resulting
in vastly different biologic effects. They have pivotal effects on oligodendrocytes and
other cell types in the oligodendrocyte lineage by serving as an energy supplier, a
participant of immunological and inflammatory functions, a source of trophic factors
and iron and a sustainer of homeostasis. Astrocytic impairment has been shown to be
directly linked to the development of neuromyelities optica (NMO). In addition, astroctyes
have also been implicated in other white matter conditions such as psychiatric disorders
and neurodegenerative diseases such as Alzheimer’s disease (AD), multiple sclerosis
(MS) and amyotrophic lateral sclerosis (ALS). Inhibiting specifically detrimental signaling
pathways in astrocytes while preserving their beneficial functions may be a promising
approach for remyelination strategies. As such, the ability to manipulate astrocyte
function represents a novel therapeutic approach that can repair the damaged myelin
that is known to occur in a variety of white matter-related disorders.
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INTRODUCTION
Human white matter makes up approximately half of the
forebrain volume, which is 3–4 times higher than that in
rodents (Hamner et al., 2011). White matter in the mammalian
central nervous system (CNS) is primarily composed of
myelin and myelinated axons. Structural and functional
completeness of myelin is critical for the reliable and efficient
transmission of information. White matter damage caused
by ischemia, hypoxia, inflammation and trauma has been
associated with the development of primary or secondary
demyelinating diseases. Demyelination of white matter is
directly correlated with a vast array of clinical symptoms
such as but not limited to sensory disturbances, paralysis,
psychiatric disorders and cognitive impairments. Despite the
variety of scientific advances that have been developed to
promote myelin repair, unfortunately, at best they have only
had marginal success. Based on the scientific literature,
we do know that cells of the oligodendrocyte lineage are
responsible for myelinating CNS axons. Oligodendrocyte
precursor cells (OPCs) represent the major source of cells that
are required to differentiate into mature oligodendrocytes.
Oligodendrocytes are responsible for myelination during
embryonic development and after a CNS demyelinating event
(Crawford et al., 2014). The inability to induce the required
production of OPCs is thought to occur due to the failure of the
microenvironment to support their regeneration (Fancy et al.,
2014).
In the CNS, astrocytes comprise the most ample and diverse
type of glial cells found in both white matter and gray
matter. They display many essential and complex functions in
adult brain and spinal cord. Specifically they are involved in
participation and regulation of synaptogenesis (Clarke and
Barres, 2013), support and nourishment of ambient parenchymal
cells (Allaman et al., 2011), homeostasis maintenance of water,
ions and neurotransmitters (Obara et al., 2008; Papadopoulos
and Verkman, 2013), development and maintenance of the
vasculature scaffold and blood-brain barrier (BBB), as well as
modulation of local blood flow (Attwell et al., 2010). As a
result, astrocytes represent a very unique cell type that can
directly influence the production and survival of cells of the
oligodendrocyte lineage.
Astrocytes respond to multiple forms of CNS insult, such as
trauma, ischemia, infection, inflammation, neurodegeneration
etc. They become ‘‘active’’ or ‘‘reactive’’ with the changes in
their morphology, physiology and gene expression (Sofroniew
and Vinters, 2010). Research suggests that reactive astrocytes are
considered detrimental to myelin repair or the re-myelination
process because of their involvement in producing scar tissue and
inhibiting OPC survival, differentiation, migration, and axonal
connectivity (Wang et al., 2011). However, in recent years, there
is accumulating evidence to suggest that astrocytes can also
create a permissive environment for oligodendrocyte lineage
expansion and differentiation. They demarcate and separate the
injured area to limit the spread of toxic factors (Fitch and
Silver, 1997) and provide tropic factor to survive the surrounding
cells of lesions (do Carmo Cunha et al., 2007). Removal
of reactive astrocytes after CNS injury led to larger lesions,
severe demyelination and oligodendrocyte death (Sofroniew and
Vinters, 2010; Haroon et al., 2011). Glial Fibrillary Acidic Protein
(GFAP) knockout mice revealed more extensive abnormalities
in the white matter than in the gray matter (Liedtke et al.,
1996).
During development and regeneration, cells from the
oligodendrocyte lineage keep in intimate contact with astrocytes
that regulate their activity and function (Moore et al., 2011).
As such, extensive research has recognized the importance of
astrocytes in the modulation of oligodendrocyte proliferation
and differentiation (Noble et al., 1988). An increasing wealth
of scientific evidence suggests that the astrocytic response
determines whether white matter lesions are able to re-myelinate
(Barnett and Linington, 2013). Irrespectively, the exact
mechanisms by which they affect re-myelination still remain
elusive. In this review, we will highlight the features of astrocytes
in CNS white matter and address the versatile roles by which
astrocytes affect OPCs and/or oligodendrocytes, ultimately
determining the degree of myelin repair or re-myelination that
occurs following white matter damage.
ASTROCYTES IN WHITE MATTER
Astrocytes are heterogeneous in many aspects, such as
development, morphology, location, protein expression
and function. They are mainly derived from radial glia in
developmental brain and are generated by subventricular stem
cells in the adult brain (Tsai et al., 2012). A bipotential progenitor
cell population that expresses A2B5 surface marker also can
differentiate into either type 2 astrocytes or oligodendrocytes
in vitro (Raff et al., 1983). The astrocytes originating from
different progenitor cells stay in place and are not replenished
by those in neighboring domains (Tsai et al., 2012). Astroglial
morphology, density and proliferation independently define the
discrete cytoarchitecture of the adult mammalian CNS (Emsley
and Macklis, 2006).
Astrocytes in gray matter are typically larger than those in
white matter. The main type of astrocytes in gray matter is the
protoplasmic astrocyte (designed as type-1 astrocytes), which are
bushy or spongiform and possesses numerous highly branched
fine processes that spread more or less radially from the soma. At
least one of the processes contacts blood vessels via perivascular
endfeet. In white matter there mainly are the fibrous astrocytes
(designed as type-2 astrocytes), which have less branched and
thicker processes with smooth, rough, straight, or undulating
appearance andmuch longer length than protoplasmic astrocytes
(Sun et al., 2009). The somas of fibrous astrocytes are often
evenly spaced and ranked in rows between the axon bundles, and
their processes terminate at nodes of Ranvier, the sites of action
potential generation (Butt, 2011).
Neighboring protoplasmic astrocytes have non-overlapping
spatial domains with little overlap of neighboring processes
(Halassa et al., 2007). They are most evident in the areas
of high synaptic density, indicating main participation of
astrocytes in modulating synaptic activities in gray matter.
Fibrous astrocytes do not have individual spatial domains and
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the processes of neighboring astrocytes overlap extensively,
suggesting their supporting or metabolic effects in white matter
(Sun and Jakobs, 2012).
Astrocytic densities and proliferation rates vary broadly
in different white matter tracts. The density of fibrous
astrocytes ranges from virtually zero in the stria terminalis to
100–125 cells/mm2 in the optic tract. Corpus callosum, the
largest fiber tract in white matter, contains 79 ± 4 GFAP-
positive cells/mm2. Dentate gyrus has the highest proliferation
rate of astrocytes across the adult mammalian CNS, followed by
subventricular zone and rostral migratory streamwhen estimated
with bromodeoxuridine (BrdU)/GFAP-positive cells (Emsley
and Macklis, 2006).
Astrocytes express intermediate filament proteins depending
on their types and developmental stages. GFAP is a kind of
characteristic biomarker which is expressed exclusively by
astrocytes in the CNS. Up-regulation of GFAP expression
under pathophysiological conditions is generally considered
as a hallmark of reactive astrocytes (Sofroniew and Vinters,
2010). GFAP, vimentin and nestin are highly expressed in
white matter compared to gray matter, so are glutamate-
aspartate transporter (GLAST), glutamate transporter-1
(GLT-1) and glutamine synthetase (GS; Goursaud et al.,
2009). Elevated GFAP expression may help GLAST anchored
in the membrane of reactive astrocytes (Sullivan et al., 2007),
indicating astrocytes in white matter have more powerful
capacity of glutamate clearance than those in gray matter.
The result is in accordance with the metabolic features
of oligodendrocyte lineage. Oligodendrocytes eventually
have to support membranes up to 100 times the weight of
their cell body, which consequently leads to extremely high
metabolic rates with the production of many toxic byproducts.
However, cells of the oligodendrocyte lineage have only
low concentration of the anti-oxidative enzyme glutathione.
Effective glutamate clearance and release of glutathione by
astrocytes are the major mechanisms preventing accumulation of
glutamate and maintaining healthy oligodendrocytes (Kimelberg
and Nedergaard, 2010).
THE EFFECT OF ASTROCYTIC ROLES ON
OLIGODENDROCYTE LINEAGE
An Energy Supplier
The adult brain occupies only 2% weight of our body but
consumes nearly 20% of glucose and oxygen. There is no direct
glucose storage in our brain cells. Under normal physiological
conditions, astrocytes and oligodendrocytes take in glucose
directly from the surrounding blood vessels through glucose
transporter 1(GLUT1). However, during hypoglycaemia or
aglycaemia, as well as during the period of increased neural
activities, astrocyte-derived glycogen is the main energy source
(Brown et al., 2003). Astrocytes are the sole repository for
glycogen particles in the mammalian CNS because glycogenesis
is confined only to astrocytes (Cataldo and Broadwell, 1986)
and also because astrocytic endfeet cover more than 90% of the
cerebral vasculate, which makes them absolutely dominant to
obtain the glucose. As such, they are the storage site of glycogen
(Baltan, 2015).
Astrocytic glycogen is released in the form of lactate by
glycolysis on demand, and lactate is transported through
monocarboxylate transporter (MCT) to ambient parenchymal
cells. Glial cells express both MCT1 and MCT4. MCT1
expression is much more pronounced in oligodendrocytes
than astrocytes (Baltan, 2015). As such, this suggests that
oligodendrocytes need much lactate via MCT1 from both
astrocytes and blood circulation as a source of energy and a
precursor of lipids to build carbon skeletons. The oxidative rate
of lactate is higher and the rate of lipid synthesis from lactate is at
least six-fold higher in oligodendrocytes than those in astrocytes
or neurons (Sánchez-Abarca et al., 2001; Rinholm et al.,
2011). Oligodendrocytes actively utilize lactate by oxidation and
lipogenesis which are required to synthesize myelin, a specialized
lipid—rich membrane. It has been found that oligodendrocytes
are more vulnerable to ischemia or hypoxia than neurons
(Pantoni et al., 1996). This may be one of the susceptible reasons
that limit their ability to re-myelinate or repair damaged areas of
myelin. Fibrous astrocytes in white matter demonstrate very high
rates of glucose oxidation through the pyruvate dehydrogenase-
catalyzed reaction and through the tricarboxylic acid cycle, while
protoplasmic astrocytes in gray matter show high biosynthetic
activity (Sánchez-Abarca et al., 2001). However, it is unclear
if the priority of astrocytic functions is corresponding to their
physiological actions in different regions and as such, this
requires further investigative research.
When glucose levels are low, L-lactate, rather than D-lactate
is responsible for protecting oligodendrocytes and OPCs and
as such rescues myelination from the reduction (Brown et al.,
2003; Rinholm et al., 2011). When glucose is sufficient, lactate
can also be preferred over glucose as a substrate for myelin
production (Rinholm et al., 2011; Baltan, 2015), implying
oligodendrocyte lineage may need additional energy and carbon
sources even in normal glucose levels. In 1994, the hypothesis
of astrocyte—neuron lactate transfer shuttle (ANLTS) was
proposed, stating lactate released from astrocytes through
glycolysis could be directed one-way traffic via MCTs from
astrocytes to neurons (Pellerin and Magistretti, 1994). This
begged the question as to whether there is a similar ‘‘lactate
shuttle’’ in white matter. Astrocytes can deliver lactate to axons
at the site of nodes of Ranvier (Baltan, 2015). It has been
found that oligodendrocytes in vitro and in vivo don’t consume
but rather are a potential source of lactate to support axon
function. These findings indicate or suggest the involvement of
a myelin—independent mechanism of axon loss (Funfschilling
et al., 2012). Whether there is lactate shuttle between astrocytes
and oligodendrocytes and how they inter-coordinate to supply
the lactate to axons are worthy of much attention.
A Participant of Immunological and
Inflammatory Functions
There is growing evidence that demonstrates astrocytes work
as a kind of immune cells. They take part in formation of
BBB, secrete cytokines and inflammatory mediators, regulate
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functions of microglia/macrophage cells, as well as present
antigen via major histocompatibility complex and indirect or
direct phagocytosis. Various observations strongly suggest that
astrocytes participate in two-way communications with immune
and inflammatory cells and thereby play an irreplaceable role
in regulating CNS immune and inflammatory reactions (Hamby
et al., 2012; Sofroniew, 2014), depending on different triggered
signaling pathways, locations and times.
Transcription factor nuclear factor kappa B (NF-κB) appears
to have an important role in understanding the inflammatory
effect of astrocytes on oligodendrocytes. Transgenic technology
(especially the deletion experiments) represents a new in vivo
tool that is being used to advance our understanding of the role
of NF-κB on astrocytes and oligodendrocytes. For example, a
mouse model of GFAP—IκBα–dominant-negative (dn) is made
by inactivating NF-κB in astrocytes through overexpression
of a dn form of the NF-κB super repressor (IκBα-dn) under
control of the GFAP promoter. In this model oligodendrocytes
are protected via reduced immune-cell infiltration (Brambilla
et al., 2014) and downregulation of adhesion molecules and
chemokines (Brambilla et al., 2009) at acute or chronic stage
of experimental autoimmune encephalomyelitis (EAE). These
molecules and chemokines include macrophages/granulocytes
(CD45hiCD11b), MHCII+ macrophages/granulocytes, B cells
(B220), activated B cells (B220MHCII), natural killers (NK1.1),
CD4 T cells, ICAM-1, VCAM-1, Itg-β5, Itg-β7, CXCL9,
CXCL10 and their receptor CXCR3 etc. At 6 days after
inducing re-myelination of EAE model in GFAP—IκBα–dn
mice, increased oligodendrogenesis, rather than the number
change of OPCs, is distributed around the epicenter. It suggests
the anti-inflammatory niche near the lesion in GFAP-IκBα-dn
group is more permissive for the differentiation of OPCs into
mature oligodendrocytes (Brambilla et al., 2009). Conditional
deletion of related factors in astrocytic NF-κB pathways, such
as Act1 (Raasch et al., 2011; Kang et al., 2013b), IkB kinase
2 (Raasch et al., 2011), NEMO (van Loo et al., 2006) and
so on, lead to its inactivity thereby exert protective influence
on the cells of oligodendrocyte lineage through inhibiting
the release of pro-inflammatory factors. Laquinimod (LAQ),
a new oral immunomodulatory compound for relapsing and
remitting multiple sclerosis (RRMS), can ameliorate myelin
injury via down-regulating NF-κB activation in astrocytes
rather than in microglia in vivo and in vitro (Brück et al.,
2012).
Chemokines represent another well-known molecular
cue expressed by astrocytes that affect oligodendrocyte
biological behavior. Astrocyte-conditioned media collected
from astrocytes pre-exposed to pro-inflammatory supernatants
lead to reduced OPCs differentiation without increasing cell
death obviously through astrocyte-derived CXCL10 (Moore
et al., 2015). Deletion of astrocytic CXCL10 delay clinical onset
but doesn’t affect progressive axon loss in EAE mice (Mills
Ko et al., 2014). Astrocytes transiently express a high level
of CXCL1 during the spinal cord development, and CXCL1-
mediated signaling through its receptor CXCR2 on OPCs
promote their proliferation via a platelet-derived growth factor
(PDGF)-AA-driven mechanism and inhibit migration
(Tsai et al., 2002). The mice models with conditional gene
deletion of CCL2 (also as monocyte chemoattractant protein-1,
MCP-1) from astrocytes have less severe EAE late in disease
and slow progression of spinal cord axon loss, involving
significantly decreasing accumulation of classically activated
M1 microglia (Moreno et al., 2014), less macrophage and T
cell inflammation (Kim et al., 2014), the lack of leukocyte
penetration and disrupted claudin -5 at the BBB in CNS (Paul
et al., 2014). However, the effects of CCL2 deletion in astrocytes
on acute stage or onset of EAE are discrepant and warrant
further researches (Kim et al., 2014; Moreno et al., 2014).
(Table 1).
Astrocytes also secrete cytokines directly or indirectly
modulating oligodendrocyte lineage and myelination. In rat
models of periventricular white matter damage (PWMD)
caused by hypoxic exposure in the peri-natal period, astrocyte-
derived tumor necrosis factor (TNF)-α and interleukin (IL)-
1β induce apoptosis of oligodendrocytes (Deng et al., 2014).
However, elective stimulation of human TNF recptor2 (TNFR2)
on astrocytes can promote OPCs differentiation into mature
oligodendrocytes by secretion of leukemia inhibitory factor
(LIF) via PI3K-PKB/Akt pathway (Fischer et al., 2014).
Interferon (IFN)-γ functions as a pro-inflammatory cytokine
at the early stage of EAE. However, in transgenic mice
expressing a signaling deficient dominant negative IFN-γ
receptor 1 specifically on astrocytes (GFAPγR14 mice), IFN-γ
signaling to astrocytes limits demyelination during acute
EAE and regulates inflammation, thus promoting remission
(Hindinger et al., 2012), indicating astrocytes participate
in limiting CNS autoimmune disease dependent upon a
neuroprotective signaling pathway via engagement of IFN-
γ receptors. Transforming growth factor (TGF) β1-induced
activation of Jagged1-Notch1 signaling in astrocytes via ALK5
and Smad3 may impact the size and differentiation of the OPC
pool in the human CNS (Zhang et al., 2010). Taken together,
astrocyte-derived immunological and inflammatory factors have
variable effects on oligodendrocyte lineage in context-specific
manners.
A Source of Trophic Factors and Iron
Astrocytes secrete many tropic factors which affect
oligodendrocyte lineage during development and remyelination
and are an indispensable part of astrocytic anti-inflammatory
function. Astrocytes are the main producer of PDGF (Kernt
et al., 2010) which could be enhanced by IFN-γ, IL-5 and
IL-17 (Moore et al., 2015) in CNS, suggesting the secretion
of astrocyte-derived PDGF can be regulated by inflammatory
stimulations. PDGF is an important survival factor for OPCs
and stimulates OPCs to either proliferation or differentiate into
mature oligodendrocytes, depending on the developmental stage
of the progenitor cells (Gard et al., 1995). Although astrocyte-
derived PDGF increases OPCs density either in development
or in focal demyelinated lesions, there is no difference in
the time course or extent of remyelination between PDGF-
increased group and wild-type group (Woodruff et al., 2004),
indicating the availability of OPCs isn’t the critical limitation of
remyelination.
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TABLE 1 | The effect of astrocyte-derived factors on oligodendrocyte lineage or EAE.
Astrocyte-derived Model Effect on oligodendrocyte Reference
factors lineage or EAE
CXCL1 Spinal cord Inhibiting OPCs migration and promoting
OPCs proliferation
Tsai et al. (2002)
CCL2 MOG-induced EAE Reducing acute and long-term
severity of clinical deficits;
Brambilla et al. (2009); Moreno et al.
(2014); and Paul et al. (2014)
Exacerbating severity of EAE at late stage Kim et al., 2014
CXCL10 MOG-induced EAE Be related with clinical onset of EAE Mills Ko et al. (2014)
IL-6 Astrocyte-conditioned media
pre-exposed to the proinflammatory
supernatants
Reducing OPCs differentiation without
an apparent increase in cell death
Moore et al. (2015)
IL-1β Hypoxic PWMD Inducing oligodendrocyte apoptosis Deng et al. (2014)
BDNF Cuprizone-induced demyelination Reversing deficits elicited
following demyelination
Fulmer et al. (2014)
BMP Spinal cord injury Inhibiting OLs differentiation Wang et al. (2011)
CNTF Spinal cord injury A pro-OLs differentiation and survival factor Hesp et al. (2015)
FGF-2 Murine hepatitis virus-induced
demyelination of the spinal cord
A potent mitogen for OPCs Albrecht et al. (2003)
IGF-1 Primary cultured astrocytes Promoting OPCs maturation Clarner et al. (2011)
LIF Astrocyte–oligodendrocyte
coculture model
Promoting OLs Maturation Ishibashi et al. (2006) and Fischer
et al. (2014)
Neuregulin Mice bearing a null mutation
in the neuregulin gene
Be necessary for the normal
development of OLs
Viehover et al. (2001)
Osteopontin Cuprizone-induced demyelination Inducing proliferation of OPCs Selvaraju et al. (2004)
PDGF Cuprizone-induced demyelination in
mice
Increasing OPCs population density Woodruff et al. (2004)




Mixed culture containing human OLs,
astrocytes, or microglia
Promoting process outgrowth
by adult human OLs
Oh and Yong (1996)
Fibroblast growth factor-2 (FGF-2), expressed by both
neurons and glia during development, mainly comes from
astrocytes after myelin injury (Messersmith et al., 2000).
It is a potent mitogen for OPCs and most of the time,
related to successful re-myelination (Messersmith et al., 2000;
Albrecht et al., 2003; Hesp et al., 2015). However, application
of FGF-2 sometimes becomes a handicap for myelin repair.
FGF-2 in combination with PDGF promotes OPCs renewal
but prevents their differentiation (Clarner et al., 2011; Ogata
et al., 2011). Elevated FGF-2 leads to severe disruption of
mature oligodendrocytes and a marked loss of myelin (Butt and
Dinsdale, 2005) or even converts mature oligodendrocytes to
a novel phenotype (Bansal and Pfeiffer, 1997). How astrocytic
FGF-2 exerts its influence hinges on the status of oligodendrocyte
lineage.
Ciliary neurotrophic factor (CNTF) is produced by astrocytes
and neurons in the CNS. It is an important survival factor for
oligodendrocytes, promotes OPCs differentiation into mature
myelin-forming cells, helps differentiated oligodendrocytes
to synthesize myelin and protects oligodendrocytes from
inflammatory insult (Stankoff et al., 2002; Modi et al., 2013).
Insulin-like growth factor-1 (IGF-1) is widely expressed in the
CNS and its expression in astrocytes is increased during and
after variety of CNS injuries (Lee et al., 1996). Astrocytic IGF-1
promotes significant increase in the number of oligodendrocytes
and myelin in vivo by directly affecting IGF type 1 receptor
(IGF1R) signaling in the cells of oligodendrocyte lineage
during normal oligodendrocyte development and myelination
(Zeger et al., 2007). IGF also contributes OPCs survival and
augments differentiation (Zumkeller, 1997). Leukemia inhibitory
factor (LIF) expressed by astrocytes is low or undetectable
in normal adult tissue (Aloisi et al., 1994). It is increased
by TNFR2-mediated activation of the PI3K-PKB/Akt pathway
in primary astrocytes, promoting OPCs differentiation into
mature myelinating oligodendrocytes (Fischer et al., 2014).
Astrocytes release LIF in response to ATP liberated from
axons firing action potentials, which promotes myelination
by mature oligodendrocytes (Ishibashi et al., 2006). However,
LIF is not always beneficial for oligodendrocyte lineage. It
inhibits myelination in a manner of concentration-dependent
biological activity (Ishibashi et al., 2006; Fischer et al.,
2014).
There are many other trophic factors affecting myelination
secreted by astrocytes, including bone morphogenetic proteins
(BMP; Wang et al., 2011), neuregulin (Viehover et al., 2001),
brain-derived neurotrophic factor (BDNF; Fulmer et al., 2014),
osteopontin (Selvaraju et al., 2004) as well as others (as
summarized inTable 1). Different trophic factors from astrocytes
exert influence on myelination and repair directly or indirectly
via autocrine or paracrine.
Iron is indispensable in mammalian metabolism because it
acts as a co-factor in many metabolic reactions and participates
in the formation of heme and iron-sulfur clusters. However,
most of brain cells can’t get iron directly from the blood
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circulation because of the existence of BBB. Astrocytes are
considered as a key regulator of iron in the CNS due to
their extensively distributed endfeet, which almost completely
covers the brain capillaries which have overwhelming location
advantages to acquire iron. Numerous receptors and transporters
are involved in the uptake, distribution and release of iron.
Through these mediators, holo-transferrin that is the main
form of iron in the systemic bloodstream enters the cytosol
through endocytosis and is released in the form of ferrous
iron (Fe2+) into cytoplasma and then into intercellular fluid.
Fe2+ is converted to Fe3+ by the enzymes on the surface
of astrocytes and then binds to apo-transferrin (that is,
iron-free transferrin) mainly synthesized and secreted by
oligodendrocytes and cells of the choroid plexus (Zakin
et al., 2002). In addition, astrocytes have been shown to
accumulate non-transferrin-bound iron (NTBI) from Fe2+
(Zakin et al., 2002; Tulpule et al., 2010) and Fe3+ (Philpott, 2012;
Figure 1).
Of all the cell types in the brain, oligodendrocytes contain the
highest level of immobilized, protein-bound iron (Todorich et al.,
2009). During development, a peak period of iron influx into the
brain coincides with the time point of the maximum amount of
myelin production (Crowe and Morgan, 1992). However, iron
may affect oligodendrocyte development during early more than
late embryogenesis (Morath and Mayer-Pröschel, 2001). In adult
brain, oligodendrocytes have high demand for iron reflected
by their high levels of ferritin and basic requirement for their
functions, oxidative metabolism and remyelination (Todorich
et al., 2009). Oligodendrocytes are unable to synthesize iron, so
they must obtain it from the ambient environment.
Ferritin is the main storage form of iron in the CNS.
Microglia exhibits stronger stain for ferritin (Connor et al., 1990)
while astrocytes express low ferritin level (Irace et al., 2005)
under physiological conditions, indicating astrocytes are vital
for the iron transportation, not the storage. As a kind of cells
connecting directly with circulating iron, the damage to any
part of astrocytic iron transportation may have an influence on
oligodendrocyte lineage. The astrocyte-specific FPN knockout
demyelinating-mouse induced by lysolecithin microinjection
produces a clear decrease in proliferation of OPCs, leading to
reduced remyelination. Lack of iron reduces the secretion of pro-
inflammatory cytokines (i.e., IL-1 and TNF-α) from microglia,
therefore resulting in down-regulation of FGF-2 and IGF-1
generated by IL-1-stimulating and TNF-α-stimulating astrocytes,
respectively (Schulz et al., 2012). Furthermore, even though
iron is supplemented after a period of iron-deprivation to
the normal serum level, morphological damage of myelin
from iron-deficiency is not easily reverted by iron reposition
(DeMaman et al., 2008). In a demyelinating rat induced by
myelin mutant, iron accumulation, expression of ferritin and
antioxidant enzyme heme oxygenase-1 (HO-1) in astrocytes
are increased, indicating a protective reaction of astrocytes to
alleviate iron-mediated cytotoxicity by regulating autologous
iron-related pathway (Izawa et al., 2010). Taken together,
astrocytes act as a direct gainer of iron in the CNS and
demonstrate pivotal effects on oligodendrocyte lineage with high
demand for iron.
A Sustainer of Homeostasis
Oligodendrocyte lineage is highly vulnerable to the excitatory
neurotransmitter glutamate because of abundant glutamate
receptors on cell surface and low content of reduced glutathione
(Sánchez-Gómez et al., 2011). Astrocytes express high levels
of glutamate transporters-excitatory amino acid transporters 1
(EAAT1, also as GLAST) and EAAT2 (also as GLT-1). Astrocytic
uptake of glutamate is the major mechanism preventing
accumulation of glutamate in the extracellular space and thus
protecting oligodendrocyte lineage from excessive activation
and excitotoxic cell death. They take in glutamate and release
glutamine (glutamate-glutamine cycle), take in glutathione
precursors and release glutathione (Kimelberg and Nedergaard,
2010). The loss of glial GLAST or GLT-1 produces elevated
extracellular glutamate levels. Decreased uptake of glutamate
by astroglial EAATs causes oligodendroglia death in hypoxic
PWMD (Murugan et al., 2013). The activation of mammalian
target of rapamycin (mTOR)-Akt-NF-γB signaling cascade,
which promotes glutamate uptake by up-regulation of astrocytic
GLT-1, may be potential protection (Ji et al., 2013). In addition,
glutamine is an important component of proteins and an
excellent energy substrate. However, oligodendrocytes do not
have GS and require glutamine from astrocytes.
Astrocytes are a key regulator of ions and water producing
a permissive microenvironment for development and survival
of oligodendrocyte lineage. Physical contacts of gap junctions
between astrocytes and oligodendrocytes form panglia syncytium
supporting a unidirectional flow of cytosolic contents from
astrocytes to oligodendrocytes. The major function of this
coupling is to provide potentially K+ spatial buffering and serves
to dissipate the increased K+ concentration in oligodendrocytes
via direct flow into astrocytic cytoplasm (Kofuji and Newman,
2004). Na+/H+ exchanger (NHE) is the most important plasma
membrane transporter involved in the astrocytic pH regulation.
Blocking NHE1 activity by the potent NHE1 inhibitor HOE-
642 significantly reduces the resting level of intracellular pH
in NHE1−/− astrocytes (Kintner et al., 2004). After hypoxia
or ischemia, NHE-1 protein is up-regulated in astrocytes
and inhibition of NHE-1 is neuroprotective by ameliorating
disruption of ionic homeostasis (Cengiz et al., 2011).
All transmembrane ionic shifts and membrane transport
mechanisms such as glutamate uptake are followed by water
movement. Unbalance of the level of extracellular ions
and neurotransmitters activates astrocytic regulatory volume
changes, resulting in the shrinkage or swelling of astrocytes
(Benesova et al., 2009). Aquaporin4 (AQP4) water channels
expressed in the perivascular end-feet of astrocytes contribute
to water homeostasis by regulating water transport and are
involved in several disease pathways (Amiry-Moghaddam et al.,
2003). In an ischemic stroke model, the presence of AQP4 was
shown to aggravate post-ischemic cytotoxic edema, while AQP4-
KO mice demonstrated an improved neurological outcome
(Wang W. W. et al., 2014). Neuromyelities optica (NMO)
is a representative condition of inflammatory demyelinating
disorder caused by targeting astrocytic AQP4. As such, this
indicates that direct damage to astrocytes can influence the
integrity of oligodendrocyte-myelin unit.
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FIGURE 1 | Iron metabolism and transport in blood-brain barrier (BBB). The above sketch demonstrates ultrastructure of BBB. The bottom figure shows how
iron metabolizes and is transported between the structures of BBB. Two atoms of ferric iron (Fe3+) are bound to one transferrin (Tf) molecule to generate
holo-transferrin, which is the main form of iron in the systemic bloodstream. Holo-transferrin interacts with surface cellular transferrin receptor 1 (TfR1) and then
enters the cytosol through endocytosis. STEAP3, the endosomal metalloreductase, reduces insoluble Fe3+ to soluble ferrous iron (Fe2+) which is released into
cytoplasma via divalent metal transporter 1(DMT1) and then into intercellular fluid mediated by ferroportin 1 (FPN1). Fe2+ is converted to Fe3+ by the enzyme of
ceruloplasmin (CP), a kind of ferroxidase, which is attached to the membrane by glycosyl phosphatidylinisotol (GPI). Fe3+ combines with apo-transferrin (iron-free
transferrin) which is mainly synthesized and secreted by oligodendrocytes and cells of the choroid plexus, and then enters the endfeet of astrocytes by endocytosis.
In endosome Fe3+ is also reduced to Fe2+ by STEAP3 and then released to the astrocytic cytoplasma. In addition, astrocytes are also able to obtain iron from other
sources. Haem-bound Fe3+ uptake is mediated by heme carrier protein 1(HCP1) and Fe3+ is liberated from internalized heme by heme oxygenase-1(HO-1). Fe3+
can be taken up by a kind of unknown Fe3+ transporter. Fe2+ can be transported into astrocytes via DMT1 directly. Fe3+ and Fe2+ transform into each other as
needed in astrocytic cytoplasma. They may be released to outside of the astrocytes by FPN1 (Fe2+), stored in ferritin (Fe3+) or enter the mitochondria by mitoferrin
which are the mitochondrial iron transporters, where iron can be used for incorporation into heme groups and iron-sulfur (Fe–S) clusters.
Many studies have shown how astrocyte-secreted extracellular
matrix (ECM) affects the behavior of oligodencrocyte lineage,
particularly OPCs. Astrocyte-derived hyaluronan may inhibit
OPC maturation (Back et al., 2005), leading to remyelination
failure. However, astrocytic ECM containing fibronectin,
vitronectin, and laminin combined with bFGF is found to
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promote oligodendroglial process extension in vitro (Oh and
Yong, 1996). Astrocytic secretion changes the components
of ECM, thereby adjusts a favorable or adverse surrounding
environment of re-myelination, depending on the protein
composition and the receptors on the OPCs. In summary,
astrocytes are a pivotal controller for homeostasis, thus
extensively influence oligodendrocyte lineage.
ASTROCYTES IN WHITE MATTER
PATHOLOGY
Demyelinating Diseases
As mentioned above, NMO is a typical demyelinating disorder
induced by direct autoimmune damage to astrocytic AQP4.
Recently there is a new group of clinical features with
positive AQP4 antibodies which is termed NMO spectrum
disorder (NMOSD) with restricted disorders, including
recurrent optic neuritis, relapsing transverse myelitis and
some encephalitic/brainstem presentations (de Seze and
Collongues, 2013). NMOSD is characteristic of positive serum
AQP4-antibody and makes it easy to find demyelinating diseases
caused by astrocytic impairments more frequent. Alexander
disease is another example of how astrocytic dysfunction
directly compromises myelination. It occurs ranging from early
infanthood to mid-life and causes developmental retardation
and seizures. It is a rare non-familial leukodystrophy, primarily
caused by mutations in the gene encoding GFAP of astrocytes
with associated increases in GFAP, the accumulation of
Rosenthal fibers and loss of myelin (Messing et al., 2012). In
the process of pathogenesis, normal protoplasmic astrocytes are
converted to severe ‘‘reactive’’ astrocytes displaying activation
of mTOR cascade, acquirement of CD44, loss of GLT-1
and diminished glutamate transporter current (Sosunov
et al., 2013). As such, this indicates that the dysfunctions
of astrocytic morphology and physiology make themselves
uncoupled to adjacent astrocytes and detrimental to neighboring
oligodendrocytes.
Multiple sclerosis (MS) is a representative of primary
demyelinating diseases. The hypothesis that MS is primarily
caused by astrocytic dysfunction is dated back to 1904.
However, their actual influence on MS still remains unclear.
In recent decades, mounting evidence shows astrocytes play
controversial roles in MS development and pathogenesis.
Astrocytes in MS take part in spontaneous myelin repair
by secreting trophic factors and providing energy and
substrates, such as lactate and iron, to myelin and axons
(reviewed by Moore et al., 2011). However, they also contribute
to myelin degradation and release pro-inflammatory and
inhibitory factors to block this process (Durfinova et al.,
2014). In chronic MS lesions, remyelination is absent or
mainly in the plaque border because of the formation of
hypertrophic astrocytes, scarring fibrous astrocytes or even
astrocytic glial scar (Clemente et al., 2013) that inhibit
OPCs migration into the lesions thereby preventing their
differentiation into mature oligodendrocytes (Bramow et al.,
2010). In general, astrocytes in the acute phase are crucial
for recovery, while their presence in the chronic phase is
inhibitory. Interestingly, MS patients seem to show higher
risk of vascular disease compared with those without
MS (Durfinova et al., 2014), and are more likely to be
hospitalized for ischemic stroke than ischemic heart disease
or myocardial infarction (Allen et al., 2008), especially within
the first year after a first-time MS diagnosis (Christiansen,
2012). It may be related to endothelial dysfunction whose
pathological mechanism is possibly linked to a loss of β2
adrenergic receptors on astrocytes of MS demyelinating lesions
(Durfinova et al., 2014).
Neurodegenerative Diseases
There is a group of distinctive iron-overloaded disorders known
as neurodegeneration with brain iron accumulation (NBIA)
diseases involved with nine identified disease genes. Among
them, aceruloplasminaemia is directly caused by abnormal
iron metabolism mainly in astrocytes. It is characteristic of
iron excess accumulation caused by gene mutations in the
brain and visceral organs, such as liver and pancreas, with
a triad of retinal degeneration, diabetes mellitus and brain
dysfunction, such as dystonia, ataxia, dementia and depression
(Skidmore et al., 2008). Astrocytic ceruloplasmin (CP) is
required for iron export from astrocytes to oxidize Fe2+ to
Fe3+, which can bind to extracellular transferring (Figure 1).
The functional loss of CP leads to marked iron overload in
astrocytes and iron deficiency in surrounding parenchymal cells,
for example, oligodendrocytes. Furthermore, iron-overloaded
astrocytes also damage ambient parenchymal cells by releasing
toxic factors.
Alzheimer’s disease (AD) is the most common form of
progressive neurodegeneration in the elderly with the major
histopathological hallmarks of extracellular amyloid-β (Aβ)
protein accumulation (known as senile plaques) and intracellular
neurofibrillary tangles (known as abnormal phosphorylation of
tau-protein filaments). At the early stage of AD, astrocytes
show atrophy with decreased GFAP-positive area and the
reduction in the somatic size and the number of primary
processes (Kulijewicz-Nawrot et al., 2012). However, at the
late stage of AD, astrogliosis is found widespread with cellular
hypertrophy and increases in the number of GFAP and
S100β protein (Olabarria et al., 2011). The interaction between
astrocytes and Aβ is changeable. Astrocytes contribute to the
clearance and degradation of Aβ (Nielsen et al., 2009) and
a reduced astrocytic response to Aβ plaques is associated
with cognitive impairment, demonstrating relative resistance
to Aβ toxicity, at least partly through astrocytic glycolysis
(Fu et al., 2015), or on the contrary, astrocytes become
an extra source of Aβ (Heneka et al., 2005). It has been
reported that Aβ-induced oligodendrocyte apoptosis might be
a critical initiating step in AD (Roth et al., 2005). As such,
astrocytes have an influence on Aβ metabolism which works
in Aβ-induced oligodendrocyte-related AD pathology. This
suggests that astrocytes may affect effectively oligodendrocytes
via Aβ pathways in AD. However, further research in
this area is required before definitive conclusions can be
drawn.
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Amyotrophic lateral sclerosis (ALS) is another ‘‘classic’’
neurodegenerative disorder which is characterized by the
progressive loss of corticospinal and spinal motor neurons and
involved in progressive reactive astrogliosis and reduction in
myelin. ALS is presented with definite white matter pathology,
and further researches have shown oligodendrocytes play an
early role in ALS, even start to degenerate before motor
neurons (Kang et al., 2013a). Oligodendrocyte lineage attempts
to compensate for oligodendrocyte loss by increasing their
proliferation and differentiation rates (reviewed by Nonneman
et al., 2014) but fails because of a loss of MCT1 (Lee et al.,
2012), mutant SOD1 or being a direct target of this disease
(Stieber et al., 2000). As a kind of cell type with multiplicity
and complexity, it is reasonable to speculate astrocytic alterations
importantly influence various neuropathological conditions,
including ALS. Riluzole, the only FDA-approved drug for
ALS, has been found enhancing astrocytic glutamate uptake
by up-regulating GLT-1 level and activity (Carbone et al.,
2012) and stimulating astrocytic syntheses of NGF, BDNF
and GDNF (Mizuta et al., 2001). The ALS model of ablating
mutant SOD1 expression selectively in astrocytes doesn’t affect
onset, but sharply slows later disease progression (Yamanaka
et al., 2008). The evidence indicates damage of oligodendrocyte
lineage mainly occurs before or at the onset of ALS,
while astrocytes exert their influence during the course of
disease.
Psychiatric Disorders
Mounting literature has displayed the close relation between
the lesions of white matter or oligodendrocyte lineage and
psychiatric disorders, including schizophrenia, bipolar disorder,
depression and autism (Haroutunian et al., 2014). In these
diseases, astrocytic changes of physiology and functions have the
potential to affect complex behavior and mood. The number of
astrocytes in postmortem histological studies of schizophrenia is
controversial. Some authors reported no change (Damadzic et al.,
2001) while others found increased (Schnieder and Dwork, 2011)
or decreased number (Hercher et al., 2014). Fibrillary astrocytes
mainly account for the reduced number (Williams et al., 2014),
and that the area fraction of GFAP-positive astrocytes decreases
and astrocytic spatial distribution demonstrates increased cell
clustering in white matter of schizophrenia patients (Hercher
et al., 2014). These disparities may be explained, at least in part,
by heterogeneity of schizophrenia symptoms and the differences
of staining methods and selected markers for assessing the
number of astrocytes.
The disturbance of neurotransmission, especially the
glutamatergic transmission, may be one of the leading
pathological mechanisms of schizophrenia (Laruelle, 2014).
As mentioned above, astrocytes are crucial for the sustenance
of glutamatergic transmission. Deletion of adenosine A2A
receptors in astrocytes disrupts glutamate homeostasis by
controlling GLT-1 activity, which is relevant to schizophrenia
(Matos et al., 2015). Mutant disrupted-in-schizophrenia 1
(DISC1) in astrocytes reduces the production of D-serine,
resulting in compensatory changes in the levels of the amino
acid transporters and N-methyl-D-aspartate receptors in the
context of tripartite synapse (Abazyan et al., 2014). The EAAT2
expression is reduced in subjects with high-risk metabotropic
glutamate receptor 3 haplotype associated with schizophrenia
(Spangaro et al., 2012). It is indicated that glutamatergic
metabolism in astrocytes may be a potential therapeutic target
for schizophrenia.
Actually, many anti-psychiatric drugs take effect through
activation of astrocytic pathways but seemingly not including
venlafaxine (Zimmermann et al., 2012; Wang J. et al., 2014).
Fluoxetine, an anti-depressive drug and one of serotonin-
specific reuptake inhibitors (SSRIs), acutely stimulates glycogen
synthesis via AKT phosphorylation (Hertz et al., 2014) and also
affects glycogenolysis (Xu et al., 2013) in astrocytes. However,
chronic treatment with fluoxetine may cause the changes of
gene expression in astrocytes (Hertz et al., 2014). Paroxetine,
amitriptyline and imipramine affect DNA methyltransferase-
1 activity via G9a in primary astrocytes (Zimmermann et al.,
2012). The chronic treatment with lithium, carbamazepine and
valproic acid results in a gradual development of intracellular
alkalinization caused by stimulation of acid extruders in
astrocytes (Hertz et al., 2014), which alters their functions and
may be associated with the fluctuation of pharmacological effects.
Altogether, astrocytes are a promising target for the therapy of
psychiatric disorders and worthy of further investigations.
CONCLUSIONS AND FUTURE
PERSPECTIVES
It is still poorly understood how astrocytes impact
oligodendrocyte lineage and how signals released or expressed by
astrocytes affect re-myelination.We have confirmed that reactive
astrogliosis is not a simple all-or-none cellular transformation
after stimulation based on previous studies. It is a continuum of
changes ranging from reversible alterations in gene expression
and cell hypertrophy to scar formation with permanent tissue
rearrangement both in vivo and in vitro. These responses are
graded, depending on the nature and severity of the insult.
After white matter injury, the effect that astrocytes exert on
oligodendrocyte lineage is changeable with different reactive
conditions, for example, time points, stimuli, signaling pathways
represent a few ways for this to occur. Inhibiting specifically
detrimental signaling pathways in astrocytes while preserving
their beneficial functions may be a promising approach.
Most of the conducted research is concerned with the
astrocytic effect on oligodendrocyte lineage or white matter
pathology through the use of rodents to mimic human
myelin-related disorders. Although some of the research in
this area demonstrates hopeful prospects, the reality is that
these interventional approaches are not applicable to repairing
damaged myelin in the human body. Although the gross
morphology of astrocytes is similar to those in rodents, human
astrocytes have larger diameter, longer and thicker processes,
more GFAP immunoreactions and more complicated synapses,
which results in a 16.5-fold increase in astrocytic volume of
human brains (Oberheim et al., 2009; Han et al., 2013). In
addition, the astrocytic diversity further complicates this issue
and leads to the difficulties in interventional pharmacological
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targeting. It is necessary to consider the heterogeneity of
astrocytes and determine the functional implications of
astrocytic reactivity in a context-specific manner. Interventions
for demyelinating diseases by manipulating astrocytes open
new therapeutic vistas and provide potential pharmacological
targets.
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